The U.S. Food and Drug Administration has amended the emergency use authorization for the Pfizer-BioNTech COVID-19 vaccine to allow for a single booster dose at least six months after completion of the primary series for people 65 years of age and older; those who are 18 through 64 and at high risk of severe…
